Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Enhancer profiling of chronic lymphocytic leukemia cells

ABSTRACT: Enhancer profiling of chronic lymphocytic leukemia cells

PROVIDER: PRJNA490189 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR7815320.fastq.gz	Fastqsanger.gz
	SRR7815330_1.fastq.gz	Fastqsanger.gz
	SRR7815330_2.fastq.gz	Fastqsanger.gz
	SRR7815340_1.fastq.gz	Fastqsanger.gz
	SRR7815340_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 64

Similar Datasets

Enhancer mapping in chronic lymphocytic leukemia

Project description:Enhancer mapping in chronic lymphocytic leukemia

| PRJNA494455 | ENA

Enhancer mapping in chronic lymphocytic leukemia

Project description:Enhancer mapping in chronic lymphocytic leukemia

| PRJNA494454 | ENA

Enhancer profiling of chronic lymphocytic leukemia cells

Project description:Enhancer profiling has emerged as a powerful approach for discovering the cis-regulatory elements that define transcriptional core regulatory circuits. Characteristic biochemical and biophysical attributes of chromatin mark active enhancer elements, which can be leveraged with genome-wide assay technologies for discovery. This includes chromatin immunoprecipitation followed by sequencing (ChIP-seq) for histone H3 acetylated lysine 27 (H3K27ac). Enhancers are also characterized by regions of open chromatin, hypersensitive to digestion by transposases measurable by the assay for transposase-accessible chromatin (ATAC-seq). By integrating measures of chromatin accessibility and domains of enriched H3K27 acetylation, we have generated enhancer landscapes from chronic lymphocytic leukemia (CLL) representative cell lines including MEC1, MEC2, OSU-CLL, and CII. Targeting enhancer signaling via BET bromodomain inhibition (using the inhibitor JQ1) disrupts enhancer-dependent gene expression as measured with RNA-sequencing in CLL cell lines.

2018-11-29 | GSE119744 | GEO

Rodrigues2019 - A mathematical model for chemoimmunotherapy of chronic lymphocytic leukemia

Project description:THis is a simple ordinary differential equation model describing chemoimmunotherapy of chronic lymphocytic leukemia, including descriptions of the combinatorial effects of chemotherapy and adoptive cellular immunotherapy.

2024-09-02 | BIOMD0000000879 | BioModels

Genetic Epidemiology of Chronic Lymphocytic Leukemia

Project description:Genetic Epidemiology of Chronic Lymphocytic Leukemia

| PRJNA448480 | ENA

Nucleosome repositioning in chronic lymphocytic leukemia

Project description:Nucleosome repositioning in chronic lymphocytic leukemia

| PRJNA666406 | ENA

Genetic Epidemiology of Chronic Lymphocytic Leukemia

Project description:Genetic Epidemiology of Chronic Lymphocytic Leukemia

| PRJNA448479 | ENA

Transcription profiling of human Chronic Lymphocytic Leukemia samples

Project description:Microarray technology was used to predict the outcome of Chronic Lymphocytic Leukemia

2007-09-04 | E-TABM-80 | biostudies-arrayexpress

MiRNA expression in chronic lymphocytic leukemia

Project description:MiRNA expression is known to be deregulated in chronic lymphocytic leukemia (CLL). To get insight into miRNA expression pattern in CLL, we compaired miRNA expression profiling of peripheral blood-derived CLL cells and the healthy donor, peripheral blood-derived B-lymphocytes. A set of differentially expressed miRNAs was revealed.

2012-05-02 | GSE31599 | GEO

Nanda2013 - B cell chronic lymphocytic leukemia A model with immune response

Project description:B cell chronic lymphocytic leukemia - A model with immune response Seema Nanda 1, , Lisette dePillis 2, and Ami Radunskaya 3, 1. Tata Institute of Fundamental Research, Centre for Applicable Mathematics, Bangalore 560065, India 2. Department of Mathematics, Harvey Mudd College, Claremont, CA 91711 3. Department of Mathematics, Pomona College, Claremont, CA, 91711, United States Abstract B cell chronic lymphocytic leukemia (B-CLL) is known to have substantial clinical heterogeneity. There is no cure, but treatments allow for disease management. However, the wide range of clinical courses experienced by B-CLL patients makes prognosis and hence treatment a significant challenge. In an attempt to study disease progression across different patients via a unified yet flexible approach, we present a mathematical model of B-CLL with immune response, that can capture both rapid and slow disease progression. This model includes four different cell populations in the peripheral blood of humans: B-CLL cells, NK cells, cytotoxic T cells and helper T cells. We analyze existing data in the medical literature, determine ranges of values for parameters of the model, and compare our model outcomes to clinical patient data. The goal of this work is to provide a tool that may shed light on factors affecting the course of disease progression in patients. This modeling tool can serve as a foundation upon which future treatments can be based. Keywords: NK cell, chronic lymphocytic leukemia, mathematical model, T cell., B-CLL.

2020-01-09 | MODEL2001090002 | BioModels

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data